In a clinicohistopathologic study of 557 patients with primary cutaneous malignant melanoma, there were fewer metastases and/or deaths from melanoma when histologic evidence of a coexisting acquired melanocytic nevus was found. A total of 130 patients with melanocytic nevus and 427 cases of melanoma without histologic evidence of a nevus (denovo) were studied. Clinical follow-up evaluation for evidence of metastases and/or death was obtained. Only ten of the patients (7.7%) with nevus-associated melanoma had metastases and/or death v 78 (18.3%) with de novo melanoma. When stratified by lesion thickness, the logrank test for survival revealed a statistically significant difference between the two groups. An overall favorable outcome seen in patients with malignant melanomas associated with acquired melanocytic nevi was found, therefore, to be independent of lesion thickness as well as six other variables reported to be related to the biologic behavior of malignant melanoma. Thus, the presence of nevus cells in a specimen of malignant melanoma portends a better prognosis and may have important implications in the biology of this neoplasm.
Download full-text PDF |
Source |
---|
Biosci Microbiota Food Health
August 2024
Department of Pharmacy, Xiangyang key Laboratory of Special Preparation of Vitiligo, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei, China.
Vitiligo is a prevalent acquired depigmenting disease that is distinguished by the depletion of functional melanocytes and epidermal melanin. Despite significant advancements in comprehending vitiligo, the precise etiology and pathogenesis of the condition remain elusive. So far, the treatment of vitiligo is still one of the most difficult dermatological challenges.
View Article and Find Full Text PDFInt J Womens Dermatol
March 2025
Private Practice, Pretoria, South Africa.
Background: Nevus of Hori (HN) has been primarily reported in patients of Eastern Asian descent, with a paucity of data regarding HN occurring in African patients. In this study, we report on South African patients with HN initially thought to have melasma.
Objective: To characterize the histopathological and clinical phenotypes of HN in African patients.
Diagn Pathol
December 2024
Department of Pathology, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, 210042, China.
Background: Isolated immunohistochemical indicators are limited to diagnose melanocytic neoplasms. This retrospective study is to assess the diagnostic value of combined immunohistochemical analysis targeting preferentially expressed antigen in melanoma (PRAME) and p16 in melanocytic neoplasms, with a detailed focus on arcal lesions.
Methods: This was a single center cohort study from January 2022 to June 2023.
J Clin Med
December 2024
20skin Four Seasons Clinic, Taichung 408, Taiwan.
Melasma is a challenging, acquired hyperpigmentary disorder. The gold standard treatment is Kligman's formulation, which contains hydroquinone, tretinoin, and dexamethasone, but its long-term use is limited by the risk of exogenous ochronosis. Cysteamine, a tyrosinase inhibitor, reduces melanocyte activity and melanin production, showing strong depigmenting effects in patients resistant to Kligman's formulation.
View Article and Find Full Text PDFDermatol Pract Concept
October 2024
Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Introduction: Vitiligo is a common acquired depigmenting dermatosis resulting from a loss of epidermal melanocytes. The academic attention to vitiligo has gradually increased over the past two decades.
Objective: We aimed to explore the current research structure and trends of vitiligo.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!